To Hold or Continue Blood Thinners? A Retrospective Analysis on Outcomes of Holmium Laser Enucleation of the Prostate in Patients Who Either Held or Continued Antiplatelet/Anticoagulation Therapy.

OBJECTIVE

To compare the outcomes between those who held or continued antiplatelet or anticoagulation therapy (APAC) for holmium laser enucleation of the prostate (HoLEP).

METHODS

We retrospectively reviewed patients on APAC who underwent HoLEP between January 2021 and August 2023 by a single surgeon at a high-volume center. APAC was further categorized to the specific medication: clopidogrel, apixaban, warfarin, rivaroxaban. Preoperative, intraoperative, and postoperative characteristics and outcomes were then compared. SPSS was used for statistical analysis with significance defined as P <.05.

RESULTS

One hundred thirty-nine patients were on APAC, of which 82 held and 57 continued APAC: 38 on clopidogrel (21 held), 20 on warfarin (11 held), 57 on apixaban (34 held), 24 on rivaroxaban (16 held). Overall, there were no significant differences between those who held versus those who continued APAC. On sub-analysis, controlling for age and prostate size, patients who held clopidogrel had shorter length of stays (11.3 hours vs 27.3 hours, P = .016), higher likelihood for same-day catheter removal (90.5% vs 47.1%, P = .002) and same-day discharge (90.5% vs 35.3%, P = .002). Patients who held warfarin had shorter procedure (61.3 minutes vs 92.2 minutes, P = .025) and morcellation time (7.36 minutes vs 18 minutes, P = .048).

CONCLUSION

HoLEP is safe and efficacious in patients whether APAC is held or continued through surgery. Holding APAC in those on clopidogrel may decrease length of stay and improve rates of same-day Foley removal and discharge. Patients who held warfarin had shorter morcellation and procedure times.